Decades-Long Tracking Reveals Genetic Clues to Blood Cancer Progression

The Wellcome Sanger Institute has unveiled findings from a landmark study that charts the long-term genetic evolution of chronic blood cancers known as myeloproliferative neoplasms, or MPNs. Published on April 20, 2026, in the prestigious journal Cancer Discovery, the research draws on over two decades of patient data to pinpoint genetic predictors that signal whether a patient's condition will remain stable or progress to more aggressive forms like myelofibrosis or leukaemia.

MPNs are a group of rare disorders where the bone marrow produces too many blood cells, affecting around 40,000 people in the UK and leading to about 4,000 new diagnoses each year. Traditionally managed with therapies to control symptoms, these cancers can sometimes transform into life-threatening diseases. This study, led by researchers at the Sanger Institute in collaboration with Cambridge University Hospitals NHS Foundation Trust, offers a new lens on why some patients thrive long-term while others face rapid decline.

Understanding Myeloproliferative Neoplasms: A Primer

Myeloproliferative neoplasms encompass conditions such as essential thrombocythaemia (ET), where platelet counts soar, polycythaemia vera (PV) with excessive red blood cells, and primary myelofibrosis (PMF), marked by bone marrow scarring. Most cases—about 90%—stem from mutations in three key genes: JAK2, CALR, or MPL. These driver mutations propel abnormal blood cell production but do not always predict progression.

The challenge lies in the remaining 10% of patients lacking these hallmark mutations. Diagnoses often rely on bone marrow biopsies, which can be invasive and inconclusive. This new research challenges that approach by demonstrating that genetic evolution patterns, rather than static snapshots, hold the true prognostic power.

The Methodology: Decades of Data and Cutting-Edge Genomics

Researchers followed 30 patients, primarily with MPNs, for periods stretching up to 25 years. They analysed more than 450 longitudinal samples—including whole blood, bone marrow, skin biopsies, and buccal swabs—using whole-genome sequencing (WGS). This generated around 200 detailed blood cell genomes, integrated with nearly 8,000 serial blood test results, treatment records, and clinical histories from electronic health systems.

By constructing phylogenetic 'family trees' of blood cell clones, the team traced mutation trajectories. This revealed two distinct evolutionary paths: stable clones with minimal genetic drift in non-progressing cases, versus dynamic mutation accumulation in those heading toward aggressive disease. For mutation-negative patients, patterns mirrored normal blood cell ageing, not malignancy.

This rigorous, patient-centred approach exemplifies the Sanger Institute's prowess in genomic epidemiology, a field where long-term cohorts meet advanced bioinformatics.

Key Discoveries: Stable vs Progressive Disease Trajectories

In stable patients, blood cell populations showed genetic steadiness—no extra mutations piled up, even under therapy. Progression cases, however, exhibited accelerating genomic instability years before symptoms worsened. These early DNA shifts act as harbingers, biologically encoding disease fate far in advance.

Particularly striking: the 10% without JAK2, CALR, or MPL mutations. Their cell evolution resembled healthy ageing, prompting calls to reclassify these as 'thrombocytosis' rather than cancer, avoiding overtreatment like chemotherapy. This aligns with 2026 British Society for Haematology guidelines, urging genetic confirmation before MPN labels.

A Patient's Journey: Alan Everitt's 34-Year Battle

Patient Alan Everitt, now 77 from Hardwick, Cambridgeshire, exemplifies the study's impact. Diagnosed with ET in 1992 at Addenbrooke's Hospital (part of Cambridge University Hospitals), he progressed to myelofibrosis and faced recurrent skin cancers. Followed for over 34 years, his case underscores the value of sustained clinical-genomic partnerships. 'It's been reassuring... I hope this research helps future patients,' Everitt shared.

His story highlights how UK NHS trusts like Cambridge's enable world-class research through integrated care and data sharing.

Photo by Adam Wilson on Unsplash

Implications for Diagnosis and Treatment in the UK

The findings advocate routine genomic monitoring in clinics, potentially via NHS genomic medicine services. Early detection of progression risks could trigger targeted interventions, sparing stable patients unnecessary risks. For the mutation-negative group, de-escalation avoids chemotherapy's long-term effects, like secondary cancers.

Lead author Dr Daniel Leongamornlert noted: 'By reconstructing cell ancestry, we saw different evolutionary patterns... informing better strategies.' Senior author Dr Jyoti Nangalia added: 'We've watched genetic code evolve ahead of clinical changes... leading to refined diagnoses and outcomes.'

Access the full study here for deeper insights into the genomic data.

Wellcome Sanger Institute: A Pillar of UK Genomic Research

Housed in Hinxton, Cambridgeshire, the Sanger Institute—funded by Wellcome—is a global leader in genomics, sequencing the human genome and pioneering cancer research. This MPN study builds on its Cancer, Ageing and Somatic Mutation programme, training PhD students and postdocs from UK universities like Cambridge and beyond.

Cancer Research UK support underscores public funding's role. Sanger's collaborations with NHS trusts exemplify translational research, bridging lab benches to patient bedsides—a model for UK higher education's research mission.

Cambridge University Hospitals: Bridging Clinic and Lab

As an NHS teaching hospital affiliated with the University of Cambridge School of Clinical Medicine, Addenbrooke's provides the clinical backbone. Haematology teams, including Dr Nangalia's dual role, facilitate serial sampling and data linkage. This symbiosis drives innovations, training junior doctors and medical students in genomic haematology.

The trust's electronic records enabled unprecedented longitudinal analysis, positioning Cambridge as a hub for blood cancer research.

Broader UK Landscape: Blood Cancer Research Momentum

UK excels in haematological oncology, with centres like the Institute of Cancer Research (ICR), University of Oxford's Big Data Institute, and Blood Cancer UK-funded trials. Recent advances include AI-driven predictions at ICR and CAR-T therapies at University College London. Sanger's work complements these, advocating genomic integration across the NHS Genomic Medicine Service.

Challenges persist: MPN underdiagnosis and progression risks. Yet, with 2026 BSH guidelines, UK leads in evidence-based care. Learn more via the British Society for Haematology guideline.

Future Directions: Genomics in Everyday Haematology

Dr Dani Skirrow of Cancer Research UK hailed the 'golden age of research' for predictive genomics. Prospects include NHS-wide WGS panels for MPNs, AI-phylogenetics for real-time monitoring, and trials targeting early progression clones. Training implications: UK medical schools must embed genomic literacy, with Sanger offering fellowships.

For patients, hope lies in precision: stable cases monitored lightly, high-risk ones preemptively treated. This study, presented at the AACR in San Diego, positions UK research at the vanguard.

Photo by Giammarco Boscaro on Unsplash

Training the Next Generation: Opportunities in UK Blood Cancer Research

Sanger's PhD programmes and clinical fellowships attract top talent from Cambridge, Oxford, and UCL. With Blood Cancer UK grants surging, roles in genomic haematology abound. The study underscores interdisciplinary skills: bioinformatics, clinical oncology, and data science—key for aspiring researchers.

UK universities like the University of Cambridge lead with integrated MD-PhD paths, fostering innovations that save lives.